Information Provided By: 
Fly News Breaks for November 1, 2019
EIDX
Nov 1, 2019 | 06:15 EDT
Barclays analyst Gena Wang downgraded Eidos Therapeutics to Equal Weight from Overweight with a price target of $45, up from $37. While the analyst believes a "meaningful commercial opportunity" exists for AG-10 given the large ATTR-CM market, she sees limited upside after the stock's recent run. Further, there's a lack of meaningful catalysts for Eidos until the Phase 3 topline data from Part A in 2021, Wang tells investors in a research note.
News For EIDX From the Last 2 Days
There are no results for your query EIDX
